文献速递眼底病与葡萄膜炎

T&E方案对比其他给药策略治疗新生血管性AMD的系统综述与Meta分析

The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis.
PubMed 文献 · Am J Ophthalmol · 2018-06-06

该系统综述与Meta分析纳入4项使用雷珠单抗的研究(共940眼),比较T&E方案与每月或PRN给药策略。12个月时T&E在视力与中央视网膜厚度改善上与每月给药相当,但优于PRN;T&E较每月注射次数更少,较PRN注射更多但就诊更少。

要点

  • 12个月时T&E与每月给药视力与解剖改善相当,但T&E注射次数更少。
  • 12个月时T&E较PRN视力增益更高,但注射次数平均多1.44次,就诊次数更少。
  • 所有纳入研究均使用雷珠单抗,未发现阿柏西普相关研究。

核心结论

  • 尽管T&E方案日益受青睐,但直接比较不同给药策略的证据有限。
  • 现有证据提示,使用雷珠单抗时,12个月T&E在疗效与安全性结局上与每月给药相当,并优于PRN给药。

研究设计与样本

  • 系统综述与Meta分析,纳入比较T&E与每月或PRN给药治疗初治AMD的研究。
  • 共纳入4项研究(总N=940眼),均使用雷珠单抗,包括2项比较T&E与每月的随机对照试验和2项比较T&E与PRN的回顾性综述。

主要发现

  • 12个月时T&E与每月给药视力改善相似,平均差异为-1.79个字母(95%CI:3.70,0.13),倾向于每月注射。
  • 12个月时T&E与每月给药中央视网膜厚度改善相似,平均差异为3.76 μm(95%CI:-13.78,21.30),倾向于每月注射。
  • T&E组视力增益高于PRN组,差异为+6.18个字母(95%CI:3.28,9.08)。
  • 与每月给药相比,T&E所需注射次数更少,12个月和24个月分别平均减少1.6次和6.9次注射。
  • 与PRN相比,T&E在12个月时平均需要多1.44次注射,但就诊次数更少。

关键数值与推荐

  • 12个月视力平均差异:T&E vs 每月为-1.79个字母(95%CI:3.70,0.13)。
  • 12个月中央视网膜厚度平均差异:T&E vs 每月为3.76 μm(95%CI:-13.78,21.30)。
  • 12个月视力增益差异:T&E vs PRN为+6.18个字母(95%CI:3.28,9.08)。
  • 注射次数差异:T&E vs 每月12个月平均-1.6次、24个月平均-6.9次;T&E vs PRN 12个月平均+1.44次。

临床怎么用

  • 使用雷珠单抗时,12个月T&E方案在疗效与安全性结局上与每月给药相当,且注射次数更少。
  • 使用雷珠单抗时,12个月T&E方案在视力增益上优于PRN给药,但注射次数更多、就诊次数更少。

局限性

  • 仅纳入4项研究,直接比较不同给药策略的头对头证据有限。
  • 未发现评估阿柏西普的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess outcomes of the treat-and-extend (T&E) injection regimen for neovascular age-related macular degeneration (AMD) as compared to either a monthly or a pro re nata (PRN) treatment strategy. DESIGN: Systematic review and meta-analysis. METHODS: Studies that compared the T&E regimen with either monthly or PRN dosing for treatment-naïve AMD were included. Trial eligibility, data extraction, and risk of bias were assessed according to Cochrane review methods. Estimates were pooled using random-effects meta-analysis. RESULTS: Four eligible studies were identified, all using ranibizumab (total N = 940 eyes), including 2 randomized controlled trials comparing T&E to monthly and 2 retrospective reviews comparing T&E to PRN. No studies evaluating aflibercept were identified. Improvements in vision and central retinal thickness were similar between T&E and monthly at 12 months, with a mean difference of -1.79 letters (95% confidence interval [CI]: 3.70, 0.13) and 3.76 μm (95% CI: -13.78, 21.30) in favor of monthly injections. In contrast, visual gains were higher in the T&E compared to the PRN group (difference of +6.18 letters, 95% CI: 3.28, 9.08). Fewer injections were required using the T&E regimen when compared to monthly (mean of -1.6 and -6.9 injections at 12 and 24 months, respectively). A mean of 1.44 more injections was required for the T&E compared to PRN regimen at 12 months; however, this was achieved with fewer visits. CONCLUSION: Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Okada M, Kandasamy R, Chong EW, et al. The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2018. PMID: 29885297. doi:10.1016/j.ajo.2018.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。